Enhanced TGF-b/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor Abstract Background. Angiotensin II (AII) and transforming growth factor-β (TGF-β) are closely involved in the pathogenesis of diabetic nephropathy (DN). AII is known to induce TGF-β production in resident renal cells, including glomerular mesangial cells and tubular epithelial cells. TGF-β receptor types I and II (TGF-βRI, II) are up-regulated in the diabetic kidney. The aim of this study was to clarify the role of AII in the regulation of the TGF-β system in the early stage of DN using AII type1a receptor-defi cient(AT1a 
Introduction
The early stage of diabetic nephropathy (DN) is characterized by renal hypertrophy, glomerular hypertrophy, glomerular hyperfi ltration, and microalbuminuria. [1] [2] [3] These changes are related to the subsequent development of glomerular morphological abnormalities and to the prognosis of DN. Many clinical and experimental studies have demonstrated that the renin-angiotensin system (RAS) is involved in the progression of DN. 4, 5 In experimental diabetic animal models, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor antagonists attenuated proteinuria and histological changes, such as glomerular hypertrophy, matrix accumulation, and macrophage infi ltration, independently of their depressor effects. 6, 7 Clinical studies have also suggested that pharmacological intervention in the RAS improves proteinuria and retards the progression of renal failure. [8] [9] [10] However, the precise mechanisms underlying the involvement of the RAS, and particularly the intrarenal RAS, in the development and progression of early-stage DN still remain elusive.
One of the characteristic pathological changes in DN is the accumulation of normal and abnormal extracellular matrix (ECM) components in the glomeruli and the interstitium of kidney. 4, 11, 12 Transforming growth factor-beta (TGF-β) is the most potent growth factor contributing to ECM accumulation, which it does by stimulating ECM pro-duction and suppressing its degradation. TGF-β isoforms and their receptors are up-regulated in both experimental and human DN. 11, 13, 14 TGF-β receptors are serine threonine kinases and they transduce various intracellular signaling when bound by TGF-β. Smad proteins are transcription factors that mediate TGF-β/activin signaling by forming complexes with each other. Smad 2 and 3 are specifi c for TGF-β signaling, and are phosphorylated by TGF-β receptor type 1 (RI) after binding with TGF-β. 15, 16 Either Smad 2 or 3 forms a heterodimer with Smad 4, and the complex immediately translocates into the nucleus and induces transcription of various genes by combining specifi c binding sites of genomic DNA. Smad 7 can be an inhibitory Smad protein that blocks the phosphorylation of Smad 2/3, counterbalancing the TGF-β signaling. 16, 17 The regulation of Smad signaling and its role in the development of DN are not yet clearly understood.
We previously reported that the characteristic changes in DN were inhibited in diabetic AT1a-receptor-defi cient (AT1a −/− ) mice despite over-expression of TGF-β in the kidney. 18 This study was designed to further elucidate the interaction between angiotensin II (AII) and TGF-β signaling in DN, with an emphasis on the expression of TGF-β receptors (TGFRs) and Smad signaling in the diabetic kidney by using AT1a −/− mice in which the intrarenal RAS is inhibited.
Materials and methods

Animals
Mutant mice were generated with a targeted replacement of the AT1a receptor locus by the lacZ gene, as previously described. 19 The heterozygous mice were intercrossed to produce homozygous (AT1a −/− ) offspring. These mice were back-crossed on C57BL/6 mice. Seventh-to eighthgeneration mice on the back-cross were used for the experiments.
Induction of diabetes mellitus
Male wild-type (AT1a +/+ ) mice (C57BL/6) and AT1a −/− mice of the seventh and eighth generations were used at 10 weeks of age. The AT1a +/+ mice were divided into a streptozotocin (STZ)-treated group (n = 13) and a control group (n = 13). AT1a −/− mice were also divided into an STZ-treated group (n = 14) and a control group (n = 8). All mice had free access to standard chow and water. Diabetes was induced by three consecutive daily intraperitoneal injections of STZ (116.7 mg/kg, total 350 mg/kg) (Sigma Chemical, St. Louis, MO, USA) in phosphate-buffered saline (PBS). 20 The control mice were injected with PBS alone. The day before treatment was set as day 0. The fi rst day that a high blood glucose level (over 200 mg/dl) was detected was set as day 1. Renal tissue was collected at 10 and 20 days after the detection of a high blood glucose level.
Immunohistochemical staining
Fresh frozen sections (4 µm) of renal cortex were prepared for the immunohistological study. Expression levels of TGF-β, and TGF-β RI and RII were analyzed by an indirect immunofl uorescence method and immunohistochemical staining, as previously described. 6 The antibodies used in this experiment were polyclonal anti-TGF-β antibody, polyclonal anti-TGF-β RI antibody, and polyclonal anti-TGF-β RII antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), FITC-conjugated anti-rabbit IgG antibody (Zymed Laboratories, San Francisco, CA, USA), and all control peptide and biotinylated secondary antibodies in the histofi ne SAB-Po kit (Nichirei, Tokyo, Japan).
Isolation of RNA and detection of TGF-β RI and RII mRNAs by RT-PCR RNA was isolated from the renal cortex by the acid guanidinium thiocyanate/phenol/chloroform extraction method. Reverse transcription-polymerase chain reaction (RT-PCR) was performed using TGF-β RII mRNA-specifi c primers, as previously described. 21 The reaction was run for 25 cycles of 1 min denaturation at 94°C, 2 min annealing at 55°C, and 3 min extension at 72°C. The reaction mixture was subjected to electrophoresis in a 1% agarose gel and stained with ethidium bromide. 22 The sequences of the primers were as follows: TGF-β RI sense 5′-CGA GAG GCA GAG ATT TAT CAG ACT G-3′, antisense 5′-TCC ACC AAT AGA ACA GCG GCG-3′, TGF-β RII sense 5′-GCA GAA CAC CTC AGA GCA GTT TG -3′, antisense 5′-ATC CAC AGA CAG AGT AGG GTC CAG-3′.
Western blot analysis for Smads
Immunoblotting was performed for Smads, as previously described. 23 Briefl y, renal cortex tissues were homogenized in ice-cold RIPA buffer containing protease inhibitors. The cell lysates were centrifuged at 18 000×g for 30 min at 4°C, and the supernatant was collected. Cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis (12.5% acrylamide gel). All samples were prepared in Laemmli buffer and boiled for 5 min before loading. Gels were blotted onto nitrocellulose membranes (Hybond-ECL, Amersham, Buckinghamshire, UK). The membranes were blocked with 5% nonfat dry milk in TBS-Tween (0.1%) at 4°C overnight, followed by incubation with the primary antibody, anti-Smad 2 antibody (0.4 µg/ml; Transduction Laboratories), anti-Smad 4 (0.2 µg/ml), anti-Smad 7 (0.2 µg/ ml), or anti-TGF-β1 (0.2 µg/ml; Santa Cruz Biotechnology) for 1 h at room temperature. The blots were washed three times in TBS-Tween for 5 min, followed by incubation with the secondary antibody conjugated with horseradish peroxidase (HRP) for 1 h at room temperature. After washing, the blots were developed with ECL Plus Western blotting detection reagents according to the protocol provided by the manufacturer (Amersham).
Isolation of nuclear extracts from renal cortex and electrophoretic mobility shift assay Nuclear extracts were prepared from renal cortex tissue as previously described. 22 Probes for Smad 3/4-specifi c elements were then obtained by end-labeling 10 pmol oligonucleotides with 20 µCi [
P] ATP and T4 polynucleotide kinase (Promega, Madison, WI, USA). The following nucleotides were used as probes: sense strand, 5′-TCG AGA GCC AGA CAA AAA GCC AGA CAT TTA GCC AGA CAC-3′; mutant 5′-TCG AGA GCT ACA TAA AAA GCT ACA TAT TTA GCT ACA TAC-3′. The binding solution contained 3 pmol labeled probe, 15 µg nuclear extracts in 21.2 mM Hepes, pH 7.9, 104 mM NaCl, 0.26 mM EDTA, 0.26 mM EGTA, 1.26 mM DTT, 5% glycerol, and 0.2 µg poly dI-dC (Sigma), and cold competitor oligonucleotides where indicated, and binding reactions were run for 30 min at room temperature. For competition experiments, 100-fold excess unlabeled probes were incubated in the reaction mixture for 20 min on ice before the addition of the labeled probe. Protein DNA complexes were resolved on a 4% nondenaturing polyacrylamide gel and electrophoresed in 1× Tris-glycine buffer. After electrophoresis, the gels were dried and protein-DNA complexes were detected by autoradiography, as previously described. 21 
Statistical analysis
All results were expressed as mean ± SEM. Analysis of variance (ANOVA) with Scheffe's test or paired Student's t-test was used to identify signifi cant differences, where appropriate. A difference of P < 0.05 was considered to be statistically signifi cant.
Results
Induction of diabetes mellitus
STZ injection resulted in an elevation of blood glucose levels within 3 or 4 days. The fi rst day after the detection of hyperglycemia (blood glucose >200 mg/dl) was set as day 1. The blood glucose levels were signifi cantly higher after STZ treatment in both AT1a
+/+ and AT1a −/− mice than in untreated controls, and there was no signifi cant difference between the two groups ( Table 1 ). The induction of diabetes mellitus was not markedly different between the two experimental groups. The body weights of diabetic AT1a
mice were signifi cantly lower at 10 and 20 days postinduction of diabetes, and similar changes were noted in diabetic AT1a −/− mice. The kidneys of diabetic AT1a +/+ mice were signifi cantly heavier at 20 days, and the total kidney/body weight ratio (TKW/BW) was signifi cantly higher throughout the course of the study. The total kidney weights (TKW) and TKW/BW of AT1a −/− mice were signifi cantly greater than those of AT1a +/+ mice at baseline, and this tendency was also observed throughout the course of the study. The TKW of the diabetic AT1a −/− mice did not change after the induction of diabetes, and TKW/BW increased mildly but not signifi cantly.
Glomerular hypertrophy was suppressed in the AT1a −/− mice Renal histology showed glomerular hypertrophy in association with mesangial area expansion at 20 days in the diabetic AT1 +/+ mice (Figs. 1-3 ). In contrast, the glomerular size in the diabetic AT1a −/− mice was not increased, although the mesangium area was increased, as reported previously. 18 Enhanced TGF-β receptor expression in the diabetic kidney First, we examined the expression of TGF-β in the kidney by immunofl uorescence. TGF-β expression in the glomeruli was signifi cantly increased in both diabetic AT1a +/+ and AT1a −/− mice compared with each baseline, but there was no signifi cant difference between the two groups (Fig. 4) . We then examined the expression of TGF-β RI and RII in mice. Note also the lack of such an increase in diabetic AT1a −/− mice the kidney by immunohistochemistry. TGF-β RI was expressed in small vessels in the interstitium and glomerular tufts at the basal condition (Figs. 5 and 6 ). The expression in the vessel wall and glomerular tufts was signifi cantly enhanced in the diabetic AT1a +/+ mice (Figs. 5 and 6). In AT1a −/− mice, the expression of TGF-β RI showed a similar distribution pattern, but the basal expression level was signifi cantly higher than that in the control AT1a +/+ mice (Fig.   6 ). The induction of diabetes slightly enhanced TGF-β RI expression, but not signifi cantly. TGF-β RII was expressed weakly in the glomerular tufts of control AT1a +/+ mice.
TGF-β RII staining in the glomerular tufts and small vessels was signifi cantly up-regulated in the diabetic AT1a +/+ mice (Fig. 5) . TGF-β RII expression in the glomerular tufts and small vessels was strongly observed at baseline in the control AT1a
. The expression was further enhanced in diabetic AT1a −/− mice. Next, we examined the mRNA expression of TGFRs in the kidney by using RT-PCR. 
, E). The staining intensity was enhanced in diabetic AT1a
+/+ mice (B, F). In the AT1a −/− mice, basal expression levels of TGF-β RI and RII were more intense than those in the AT1a +/+ mice, and the intensity was further increased in the diabetic AT1 −/− mice (×400) Fig. 6 . Glomerular expression levels of TGF-β RI and RII measured semiquantitatively in diabetic mice. A TGF-β RI. B TGF-β RII. TGF-β RI and RII expression in the glomerulus was semiquantitated by a grading system measuring staining distribution and intensity. The staining scores for TGF-β RI and RII were signifi cantly increased in the diabetic AT1a +/+ mice. In the AT1a −/− mice, baseline TGF-β RI/II expression was increased in the glomeruli compared with the AT1a +/+ mice. The enhanced TGF-β RI/II expression was sustained after diabetic induction. Data are expressed as means ± SD TGF-β RI mRNA was detected at baseline, and the expression level was markedly enhanced in diabetic AT1a +/+ mice (Fig. 7) , which paralleled the immunohistochemical fi ndings. TGF-β RII expression was also detectable, and the expression level was mildly increased after the induction of diabetes in both AT1a +/+ and AT1a −/− mice.
Enhanced Smad signaling in diabetic AT1a
+/+ and
We next focused on Smad signaling because the TGF-β/ TGF-β R pathway in the diabetic AT1a −/− mice was not suppressed in spite of amelioration of glomerular hypertrophy. Smad 2, 4, and 7 protein levels in the renal cortex were analyzed using Western blotting. Smad 2 and 4 were abundantly present in the renal cortex in both the AT1a +/+ and AT1a −/− mice (Fig. 8) . Smad 2/4 protein contents were signifi cantly reduced after the induction of diabetes in AT1a
mice. The reduction of Smad 2/4 protein levels was also observed in diabetic AT1a −/− mice, but the magnitude of the reduction was less than that in the diabetic AT1a +/+ mice.
Smad 7 was also expressed in the renal cortex, along with Smad 2/4 proteins. The expression level of Smad 7 did not signifi cantly change after the induction of diabetes. We performed gel shift assay specifi c for Smad 3/4 using nuclear extracts from the renal cortex to evaluate TGF-β-specifi c Smad signaling. A protein complex binding to the labeled oligonucleotide was observed in the control condition, and the intensity of the band was increased in the diabetic AT1a +/+ mice, suggesting an increase of Smad 3/4 complex that translocated into the nucleus. In contrast, Smad 3/4 complex in the nuclear extracts of the control AT1 −/− mice was unexpectedly increased, and the enhancement was sustained in the diabetic state (Fig. 9 ).
Discussion
The early stage of DN is characterized by glomerular hypertrophy and the accumulation of ECM in the glomerulus and tubulointerstitium. TGF-β is considered to be a key cytokine that directly contributes to ECM accumulation by increasing matrix synthesis in resident renal cells and decreasing its degradation. 3 In this study, the TGF-β/TGF-β R/Smad pathway was enhanced in diabetic kidney. A complete inhibition of AT1a-mediated signals did not affect the up-regulation of expression of TGF-β and its receptors in mice with STZ-induced DN. Inversely, TGFRs, particularly type II, were up-regulated in AT1a −/− mice at baseline in parallel with a continuous enhancement of TGF-β-specifi c Smad signals in the kidney of AT1a −/− mice.
TGF-β transduces its signals via TGFRs. The TGFR superfamily consists mainly of two broad classes of receptor serine threonine kinases, types I and II. 15, 16 TGF-β binds to 16 TGFR expression is known to be up-regulated in various experimental models and in human renal diseases, including DN. 24, 25 A few reports show that TGF-β RII expression in the kidney was increased in both the STZ-induced diabetes and db/db mouse models as well as in human DN. 26, 27 Our data are consistent with their fi ndings. The TGF-β/TGF-β R system is enhanced by hyperglycemia per se and mediated by other factors, including AII and other vasomodulatory factors such as thromboxane, endothelins, platelet-derived growth factor, and insulin-like growth factor-1. 1, 3, 5 Pharmaceutical blockade of RAS by ACEI or AT1 blockers ameliorates the progression of DN in experimental models and human DN, partly by suppressing TGF-β production in the kidneys. 28, 29 However, the effect of angiotensin blockade on TGFR expression is not yet clear. There are few reports concerning TGFR expression and angiotensin blockade. 6, 30 In our study, the induction of diabetes signifi cantly increased TGF-β RI and RII expression in the glomerular tufts and vasculature. We also found that TGF-β RI and II expressions in the kidney of AT1a −/− mice were increased without the induction of diabetes to a level similar to that in control diabetic mice. The induction of diabetes in the AT1a −/− mice signifi cantly increased the TGFRs in the early stage of the kidney. One of our aims in this experiment was to investigate the infl uence of AII on Smad signaling. Previous studies have shown that AII activates the TGF-β/Smad system, and the TGF-β/Smad system involves the development of DN. [31] [32] [33] Consequently, we hypothesized that the complete inhibition of the AT1aR-mediated signal benefi cially infl uenced the TGF-β/Smad system, thus contributing to the progression of DN. In this study, the reduction and subsequent increase of renal Smad 2/4 proteins was similarly observed in the diabetic AT1a −/− mice. However, the Smad 3/4 complex was unexpectedly increased at baseline and the increase was sustained during the course of the study. This was associated with the up-regulation of TGF-β and TGFRs. It is not known why the inhibition of AII led to the up-regulation and activation of the TGF-β/Smad system. There has recently been a report that AII activates Smad signaling by TGF-β-dependent and -independent ways. 34, 35 In addition, it is suggested that advanced glycation end products (AGEs) activate Smad signaling via TGF-β-dependent and -independent mechanisms. 36 AII is known to induce several intracellular signaling pathways, including the PKC pathway and the MAP kinase pathway, via AT1R. The interaction of MAP kinase and Smad signaling has recently been reported 37, 38 The activation of MAP kinase inhibits Smad signaling by blocking translocation of Smad 2/4 or 3/4 complexes. Further studies of cross-talk among RAS, AII, TGF-β, Smad signaling, and MAP kinase in resident renal cells are required to clarify the mechanisms.
The results from genetically defi cient animals sometimes confl ict with those from pharmacological blockade. Knocked-out mice in the RAS have shown paradoxical progressive renal injury with vasculopathy. 39 In addition, up-regulation of TGF-β in the kidney was reported in angiotensinogen-defi cient mice. In our study, up-regulation of TGFRs was noted particularly in small vessels and glomeruli, which is similar to the localization of AT1aR. Although we had no chance to study whether or not a similar abnor-mality in the TGF-β/TGFR/Smad pathway might exist in other KO mice of the RAS component, the abnormalities that we detected in the AT1a −/− mice might be a clue to exploring the intracellular cross-talk between factors that are physiologically important and that play key roles in the progression of renal diseases. Another fi nding of our study was the suppression of Smad 7. Smad 7 is induced by Smad 2/4 or 3/4 transactivation and inhibits Smad 2/3 phosphorylation, which exerts a negative feedback. 16, 17, 40 Smad 7 in the wild-type diabetic kidney was not increased despite activation of the TGF-β/ Smad pathway. 41 This inhibition was also observed in the diabetic AT1a −/− mice. 42 TGF-β has numerous biological effects that are physiologically important. New strategies are necessary to control the pathological function of TGF-β more selectively in order to prevent renal fi brosis.
In conclusion, we have demonstrated signifi cant increases in the expression of TGF-β receptors and TGF-β-specifi c Smad signaling in the early stage of the diabetic kidney. Complete blockade of AT1a-mediated signals had little effect on the enhanced TGF-β/Smad system in the diabetic kidney, which might refl ect the complexity of the pathogenesis of DN.
